Characteristics | Cases (n = 19) |
---|---|
Patient age, median (range), years | 33 (3–57) |
Sex | |
Male | 13 |
Female | 6 |
Diagnosis | |
AML | 3 |
ALL | 7 |
MDS | 7 |
PID | 2 |
Pre-HSCT EBV status, donor/recipient | |
Positive/positive | 19 |
MNC, median (range), × 108/kg | 5.17 (2.53–9.59) |
CD34+ cell absolute count, median(range), ×106/kg | 6.37 (1.61–11.13) |
CD3+ cell absolute count, median(range), ×108/kg | 2.76 (0.82–7.83) |
Engraftment | |
White cells, median (range), days | 12 (10–18) |
Platelets, median (range), days | 13 (9–18) |
Acute graft-versus-host disease, n | |
No | 7 |
I–II degree | 10 |
III–IV degree | 2 |
EBV infection after HSCT within 100 days | |
No | 9 |
EBV-DNAemia | 5 |
EBV disease | 5 |
CSA stop | |
No | 4 |
Yes | 15 |
CSA stopping time, median (range), days | 32.5 (4–88) |